The Lupus Foundation of America is a U.S.-based nonprofit health organization focused on improving the lives of people affected by lupus, an autoimmune disease. Founded in 1977 and headquartered in Washington, D.C., the foundation supports research, education, patient services, and policy advocacy related to lupus.
Its work includes funding and facilitating scientific studies, offering patient and caregiver resources (such as information, support programs, and referral services), and providing professional education for clinicians to improve diagnosis and care. The organization collaborates with researchers, medical centers, and public agencies, coordinates public awareness initiatives, and advocates for increased research investment and access to effective treatments across the United States.
Phase 2 data show FcRn blocker nipocalimab reduced SLE activity versus placebo, with larger benefit in autoantibody‑positive patients and no new safety signals.
FDA approves Gazyva for lupus nephritis, showing superior results in trials, offering a new treatment option to prevent kidney disease progression.
